Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.
News|Articles|August 18, 2026
Closing the Gap: Innovation vs Access in Blood Cancer Care
Author(s)Maggie L. Shaw
Fact checked by: Laura Joszt, MA
Cell therapy and targeted agents are transforming blood cancer outcomes, but infrastructure, funding, and workforce gaps are limiting who can access them.
Advertisement
Advertisement
Multiple myeloma was once described as a death sentence. Today, thanks to proteasome inhibitors, immunomodulatory drugs (IMiDs), anti-CD38 antibodies, and chimeric antigen receptor (CAR) T-cell therapy, patients are living years—sometimes decades—longer than previous survival estimates. Similar transformations are underway across
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
Advertisement
Advertisement